News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
696,323 Results
Type
Article (39554)
Company Profile (247)
Press Release (656522)
Section
Business (204103)
Career Advice (2007)
Deals (35412)
Drug Delivery (94)
Drug Development (81010)
Employer Resources (172)
FDA (16155)
Job Trends (14843)
News (345047)
Policy (32500)
Tag
2024 BioCapital Digital (6)
2024 BioForest Digital (1)
2024 BioForest Standard (1)
2024 BioMidwest Digital (7)
2024 BioMidwest Standard (1)
2024 Bio NC Digital (4)
2024 Bio NC Standard (2)
2024 Biotech Bay Standard (17)
2024 Biotech Beach Digital (8)
2024 Biotech Beach Standard (4)
2024 Genetown Digital (5)
2024 Genetown Standard (9)
2024 Lone Star Bio Digital (4)
2024 Pharm Country Digital (5)
2024 Pharm Country Standard (5)
2025 BioForest Digital (1)
2025 Lone Star Bio Digital (5)
2026 BioCapital Standard (1)
2026 BioMidwest Elite (1)
2026 Biotech Bay Standard (1)
2026 Biotech Beach Elite (1)
2026 Genetown Elite (2)
2026 Pharm Country Standard (1)
Academia (2546)
Accelerated approval (4)
Adcomms (20)
Allergies (80)
Alliances (49375)
ALS (83)
Alzheimer's disease (1356)
Antibody-drug conjugate (ADC) (109)
Approvals (16157)
Artificial intelligence (233)
Autoimmune disease (16)
Automation (14)
Bankruptcy (360)
Best Places to Work (11636)
BIOSECURE Act (18)
Biosimilars (101)
Biotechnology (175)
Bladder cancer (58)
Brain cancer (25)
Breast cancer (250)
Cancer (2012)
Cardiovascular disease (162)
Career advice (1673)
Career pathing (29)
CAR-T (140)
Cell therapy (397)
Cervical cancer (19)
Clinical research (65732)
Collaboration (768)
Compensation (463)
Complete response letters (19)
COVID-19 (2581)
CRISPR (35)
C-suite (211)
Cystic fibrosis (98)
Data (1977)
Decentralized trials (2)
Denatured (16)
Depression (38)
Diabetes (249)
Diagnostics (6336)
Digital health (17)
Diversity (8)
Diversity, equity & inclusion (44)
Drug discovery (113)
Drug pricing (95)
Drug shortages (25)
Duchenne muscular dystrophy (85)
Earnings (86215)
Editorial (31)
Employer branding (21)
Employer resources (146)
Events (111699)
Executive appointments (649)
FDA (17273)
Featured Employer (47)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (4)
Frontotemporal dementia (7)
Funding (690)
Gene editing (96)
Generative AI (18)
Gene therapy (278)
GLP-1 (685)
Government (4381)
Grass and pollen (4)
Guidances (49)
Healthcare (18808)
Huntington's disease (22)
IgA nephropathy (23)
Immunology and inflammation (103)
Indications (26)
Infectious disease (2713)
Inflammatory bowel disease (132)
Inflation Reduction Act (8)
Influenza (48)
Intellectual property (87)
Interviews (311)
IPO (16486)
IRA (40)
Job creations (3628)
Job search strategy (1422)
Kidney cancer (9)
Labor market (34)
Layoffs (454)
Leadership (15)
Legal (7901)
Liver cancer (70)
Lung cancer (293)
Lymphoma (134)
Machine learning (4)
Management (58)
Manufacturing (268)
MASH (61)
Medical device (13326)
Medtech (13331)
Mergers & acquisitions (19406)
Metabolic disorders (632)
Multiple sclerosis (72)
NASH (16)
Neurodegenerative disease (80)
Neuropsychiatric disorders (24)
Neuroscience (1839)
NextGen: Class of 2025 (6512)
Non-profit (4476)
Northern California (2445)
Now hiring (37)
Obesity (340)
Opinion (201)
Ovarian cancer (72)
Pain (77)
Pancreatic cancer (76)
Parkinson's disease (137)
Partnered (20)
Patents (204)
Patient recruitment (96)
Peanut (46)
People (57100)
Pharmaceutical (63)
Pharmacy benefit managers (18)
Phase I (20471)
Phase II (28945)
Phase III (21574)
Pipeline (1053)
Podcasts (45)
Policy (113)
Postmarket research (2563)
Preclinical (8657)
Press Release (64)
Prostate cancer (94)
Psychedelics (30)
Radiopharmaceuticals (244)
Rare diseases (359)
Real estate (5901)
Recruiting (65)
Regulatory (22147)
Reports (46)
Research institute (2318)
Resumes & cover letters (349)
Rett syndrome (4)
RNA editing (4)
RSV (39)
Schizophrenia (64)
Series A (121)
Series B (78)
Service/supplier (11)
Sickle cell disease (51)
Southern California (2113)
Special edition (14)
Spinal muscular atrophy (147)
Sponsored (28)
Startups (3571)
State (2)
Stomach cancer (13)
Supply chain (60)
Tariffs (11)
The Weekly (27)
United States (21285)
Vaccines (657)
Venture capitalists (37)
Webinars (12)
Weight loss (224)
Women's health (33)
Worklife (15)
Date
Today (106)
Last 7 days (727)
Last 30 days (2700)
Last 365 days (33489)
2025 (8221)
2024 (35218)
2023 (40076)
2022 (51173)
2021 (55710)
2020 (54083)
2019 (46538)
2018 (35018)
2017 (32109)
2016 (31480)
2015 (37552)
2014 (31318)
2013 (26345)
2012 (28570)
2011 (29263)
2010 (27328)
Location
Africa (718)
Alabama (49)
Alaska (7)
Arizona (224)
Arkansas (13)
Asia (37710)
Australia (6166)
California (5564)
Canada (1876)
China (476)
Colorado (247)
Connecticut (256)
Delaware (128)
Europe (80866)
Florida (827)
Georgia (196)
Idaho (57)
Illinois (500)
India (24)
Indiana (291)
Iowa (9)
Japan (142)
Kansas (100)
Kentucky (23)
Louisiana (8)
Maine (61)
Maryland (832)
Massachusetts (4189)
Michigan (209)
Minnesota (370)
Mississippi (2)
Missouri (77)
Montana (27)
Nebraska (25)
Nevada (56)
New Hampshire (62)
New Jersey (1589)
New Mexico (28)
New York (1601)
North Carolina (921)
North Dakota (7)
Northern California (2445)
Ohio (192)
Oklahoma (14)
Oregon (33)
Pennsylvania (1261)
Puerto Rico (9)
Rhode Island (27)
South America (1094)
South Carolina (18)
South Dakota (1)
Southern California (2113)
Tennessee (94)
Texas (831)
Utah (164)
Virginia (130)
Washington D.C. (57)
Washington State (514)
West Virginia (3)
Wisconsin (49)
696,323 Results for "exicure inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Exicure, Inc. Reports Full Year 2024 Financial Results
March 18, 2025
·
7 min read
Press Releases
Exicure, Inc. (Nasdaq: XCUR) Announces Issuance of New Patent in Australia
March 14, 2025
·
2 min read
Press Releases
Exicure, Inc. Announces Purchase Agreement with GPCR Therapeutics Inc.
January 23, 2025
·
5 min read
Deals
Exicure, Inc. Received Nasdaq Notice of a Delisting Determination
Exicure, Inc. (“Exicure” or the “Company”) (Nasdaq: XCUR), announced today it received notice of a delisting determination (the “Staff Delisting Determination”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”).
May 23, 2024
·
3 min read
Press Releases
Exicure, Inc. Partners with GPCR Therapeutics to Fuel New Growth in Biotech
December 26, 2024
·
4 min read
BioMidwest
Exicure, Inc. Reports First Quarter 2024 Financial Results
Exicure, Inc. (Nasdaq: XCUR, the “Company”), has historically been an early-stage biotechnology company focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets.
June 17, 2024
·
6 min read
Business
Exicure, Inc. Reports Full Year 2023 Financial Results
Exicure, Inc. (Nasdaq: XCUR) has historically been an early-stage biotechnology company focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets.
June 6, 2024
·
6 min read
Business
Exicure, Inc. Reports Third Quarter 2023 Financial Results
Exicure, Inc. (Nasdaq: XCUR), has historically been an early-stage biotechnology company focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets.
May 16, 2024
·
6 min read
Business
Exicure, Inc. and Bluejay Therapeutics Inc. Enter into a Patent License Agreement to Develop Cavrotolimod for the Treatment of Hepatitis
Exicure, Inc., (NASDAQ:XCUR) and Bluejay Therapeutics, Inc., a private clinical stage biopharmaceutical company focused on viral and liver diseases, announced today that Bluejay Therapeutics, Inc. (“Bluejay”) and Exicure, Inc. (“Exicure”) entered into a patent license agreement to develop cavrotolimod for potential treatment for hepatitis.
February 5, 2024
·
3 min read
Policy
Exicure, Inc. Received Nasdaq Delinquency Notice on Late Filing of its Form 10-K
Exicure, Inc., announced it received a notice of non-compliance from Nasdaq Stock Market LLC on April 17, 2024 notifying the Company that, as a result of the Company’s failure to timely file its Annual Report on Form 10-K for the year ended December 31, 2023, the Company is not in compliance with Nasdaq Listing Rule 5250, which requires listed companies to timely file all periodic financial reports with the U.S.
April 22, 2024
·
3 min read
1 of 69,633
Next